CA-051

About Concentric Analgesics

Concentric Analgesics is a clinical-stage biotech developing a novel platform of non-opioid pain therapeutics. Its lead candidate, vocacapsaicin (CA-008), is a Phase 3-ready prodrug that converts to capsaicin to provide durable, localized pain relief without systemic side effects or numbness. The company aims to address significant unmet needs in postsurgical and chronic pain markets, targeting the reduction of opioid dependence and associated healthcare costs. Its pipeline also includes programs for cancer-related pain and osteoarthritis.

Therapeutic Areas